Strides Pharma Science Limited Total Liabilities
Strides Pharma Science Limited total liabilities. Based on the latest financial reports, Strides Pharma Science Limited (STAR) has total liabilities worth Rs37.78 Billion INR (≈ $408.57 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check STAR financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Strides Pharma Science Limited (2005–2026)
Total liabilities of Strides Pharma Science Limited from 2005 to 2026. This chart illustrates how Strides Pharma Science Limited's total liabilities have evolved over time, based on quarterly financial data. Explore STAR long-term investment intensity to see how much of total assets are deployed in long-term investments.
Strides Pharma Science Limited Competitors by Total Liabilities
The table below lists competitors of Strides Pharma Science Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Artivion Inc
NYSE:AORT
|
USA | $626.35 Million |
|
Sri Trang Agro-Industry Public Company Limited
BK:STA
|
Thailand | ฿47.56 Billion |
|
Suzhou GYZ Electronic Technology Co. Ltd. A
SHG:688260
|
China | CN¥1.41 Billion |
|
Avia Avian PT Tbk
JK:AVIA
|
Indonesia | Rp1.33 Trillion |
|
China Reinsurance (Group) Corporation
F:C53
|
Germany | €408.45 Billion |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH-R
|
Thailand | ฿3.43 Billion |
|
Pet Valu Holdings Ltd
TO:PET
|
Canada | CA$951.62 Million |
|
Huizhou China Eagle Electronic Technology Co Ltd
SHE:002579
|
China | CN¥3.99 Billion |
Liability Composition Analysis (2005–2026)
This chart breaks down Strides Pharma Science Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Strides Pharma Science Limited total assets.
Liquidity & Leverage Metrics
Strides Pharma Science Limited Total Liabilities Ratios Explained
Strides Pharma Science Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Strides Pharma Science Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Strides Pharma Science Limited (2005–2026)
The table below shows the annual total liabilities of Strides Pharma Science Limited from 2005 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs37.78 Billion ≈ $408.57 Million |
+9.12% |
| 2025-03-31 | Rs34.62 Billion ≈ $374.43 Million |
-8.12% |
| 2024-03-31 | Rs37.68 Billion ≈ $407.50 Million |
-15.62% |
| 2023-03-31 | Rs44.66 Billion ≈ $482.93 Million |
-2.77% |
| 2022-03-31 | Rs45.93 Billion ≈ $496.67 Million |
+9.32% |
| 2021-03-31 | Rs42.01 Billion ≈ $454.32 Million |
+18.10% |
| 2020-03-31 | Rs35.57 Billion ≈ $384.68 Million |
-31.65% |
| 2019-03-31 | Rs52.04 Billion ≈ $562.78 Million |
+32.26% |
| 2018-03-31 | Rs39.35 Billion ≈ $425.51 Million |
-24.95% |
| 2017-03-31 | Rs52.42 Billion ≈ $566.94 Million |
+10.29% |
| 2016-03-31 | Rs47.53 Billion ≈ $514.03 Million |
+259.41% |
| 2015-03-31 | Rs13.22 Billion ≈ $143.02 Million |
+30.10% |
| 2014-03-31 | Rs10.17 Billion ≈ $109.93 Million |
-62.34% |
| 2013-03-31 | Rs26.99 Billion ≈ $291.93 Million |
-33.29% |
| 2012-03-31 | Rs40.46 Billion ≈ $437.59 Million |
+37.72% |
| 2011-03-31 | Rs29.38 Billion ≈ $317.75 Million |
+37.28% |
| 2010-03-31 | Rs21.40 Billion ≈ $231.46 Million |
+23.59% |
| 2009-03-31 | Rs17.32 Billion ≈ $187.28 Million |
-0.47% |
| 2008-03-31 | Rs17.40 Billion ≈ $188.17 Million |
+118.53% |
| 2007-03-31 | Rs7.96 Billion ≈ $86.11 Million |
+35.10% |
| 2006-03-31 | Rs5.89 Billion ≈ $63.74 Million |
+79.15% |
| 2005-03-31 | Rs3.29 Billion ≈ $35.58 Million |
-- |
About Strides Pharma Science Limited
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasalsprays, topical formulations, an… Read more